Skip to main content

Beneficial ownership — 13D / 13G

87,281 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Lind Global Fund II LP WINT Windtree Therapeutics Inc 13G/A 5.3% 2y
Muhleisen, Dan D. NNI Nelnet Inc 13G/A 14% 2y
Mizuho Financial Group, Inc. TGAA Target Global Acquisition I Corp. Class A Ordinary Share 13G 7.94% 2y
Lind Global Fund II LP AUMN Golden Minerals Co 13G/A 9.9% 2y
Henry R. Kravis KKR KKR & Co. Inc. 13G/A 9.4% 2y
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC FHB First Hawaiian, Inc. 13G/A 10.15% 2y
GATES FOUNDATION TRUST CAF Morgan Stanley China A Share Fund, Inc. 13G/A 7.6% 2y
Heard Capital LLC ATEX Anterix Inc. 13G/A 9.75% 2y
Fortune Enterprise Holdings Limited BDAI Biddance AI Systems, Inc. 13G 56.9% 2y
Dodge & Cox OXY Occidental Petroleum Corp 13G/A 10.7% 2y
Aaron Cowen AKLI Akili, Inc. Common Stock 13G/A 6% 2y
JANUS HENDERSON GROUP PLC SLNO Soleno Therapeutics Inc 13G/A 8.3% 2y
SUVRETTA CAPITAL MANAGEMENT, LLC FULC Fulcrum Therapeutics, Inc. 13G/A 8.9% 2y
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC GBLI Global Indemnity Group, LLC 13G/A 10.39% 2y
MMCAP International Inc. SPC XBP XBP Global Holdings, Inc. 13G/A 0% 2y
Prosight Management, LP LBPH Longboard Pharmaceuticals, Inc. Common Stock 13G/A 0% 2y
Dodge & Cox LYB LyondellBasell Industries N.V. 13G/A 5% 2y
SB INVESTMENT ADVISERS (UK) LTD VIR Vir Biotechnology, Inc. 13G/A 12.4% 2y
Ned N. Fleming, III ROAD Construction Partners, Inc. 13G/A 13.1% 2y
Mizuho Financial Group, Inc. APXI APx Acquisition Corp. I Class A Ordinary Share 13G 5.99% 2y
BOOTHBAY FUND MANAGEMENT, LLC STI Solidion Technology Inc. 13G/A 0% 2y
Avidity Partners Management LP CYT Cyteir Therapeutics, Inc. Common Stock 13G/A 0% 2y
SB INVESTMENT ADVISERS (UK) LTD COMP Compass, Inc. 13G/A 21.2% 2y
BlackRock Inc. XIFR XPLR Infrastructure, LP 13G/A 7.7% 2y
Polar Asset Management Partners Inc. JWAC Jupiter Wellness Acquisition Corp. Class A Common Stock 13G/A 4.9% 2y
Banyan Partners III Ltd. YSG Yatsen Holding Ltd 13G/A 8% 2y
Archon Capital Management LLC APYX Apyx Medical Corp 13G/A 9.96% 2y
Karpus Management, Inc. KVACF Keen Vision Acquisition Corp. 13G 6.6% 2y
Mizuho Financial Group, Inc. CURR Currenc Group Inc. 13G 7.4% 2y
SOFTBANK GROUP CORP. NMRA Neumora Therapeutics, Inc. 13G 5% 2y
Shlomi Ben Haim FROG JFrog Ltd 13G/A 4.4% 2y
Richard A. Miller CRVS Corvus Pharmaceuticals, Inc. 13G/A 7.19% 2y
RCP Opp Fund I GP, L.P. VCTR Victory Capital Holdings, Inc. 13G/A 1.87% 2y
Hill City Capital, LP CCLP CSI Compressco LP 13G/A 5.25% 2y
Focus Impact Sponsor, LLC DEVSF DevvStream Legacy Corp. 13G/A 90.8% 2y
TCG Crossover GP I, LLC CBAY Cymabay Therapeutics 13G/A 0% 2y
Polar Capital Holdings Plc CLDX Celldex Therapeutics, Inc. 13G 5.73% 2y
Champlain Investment Partners, LLC FRPT Freshpet, Inc. 13G/A 7.86% 2y
BlackRock Inc. FTV Fortive Corp 13G/A 9% 2y
Lind Global Fund II LP TTOO T2 Biosystems, Inc 13G/A 0.5% 2y
ALKEON CAPITAL MANAGEMENT LLC KROS Keros Therapeutics, Inc. 13G/A 5% 2y
BANK OF AMERICA CORP /DE/ RVT Royce Small-Cap Trust, Inc. 13G 5.1% 2y
Stonepine Capital Management, LLC EOLS Evolus, Inc. 13G/A 9.3% 2y
JANUS HENDERSON GROUP PLC CCSI Consensus Cloud Solutions, Inc. 13G/A 8.2% 2y
Karpus Management, Inc. MCAF Mountain Crest Acquisition Corp. IV Common Stock 13G/A 8.66% 2y
Tarang P. Amin ELF e.l.f. Beauty, Inc. 13G/A 3.4% 2y
Nicholas T. Curtis LNSR LENSAR, Inc. 13G/A 7.9% 2y
Delores B. Weaver SHOE Shoe Station Group Inc 13G/A 32.8% 2y
Value Base Ltd. CGNT Cognyte Software Ltd. 13G/A 5.25% 2y
Lip-Bu Tan CRDO Credo Technology Group Holding Ltd 13G/A 2.2% 2y